Stocks That Have Surged Higher Year To Date: $GNUS $AIM $APT

*If You Own GNUS, AIM, APT Then Click Here to Join Our Community Of Traders

The Market Signal was created as a platform to help investors, if you own (NYSE:GNUS), (NASDAQ:AIM) or (NASDAQ:APT) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/Free-Report/NOW
(Click the link above or copy, paste and hit enter in your browser for your report)

Michael Uslan To Lead IP development at Genius Brands

https://themarketsignal.com/Free-Report/GNUS

(Click the link above or copy, paste and hit enter in your browser for your report)

Genius Brands (NYSE:GNUS) stock is up 483.06% year to date. The producer and the brand creator behind Batman movies, Michael Uslan has turned high sight on Genius Brand's superhero Intellectual properties. Uslan will work as an advisor of the company to create amazing stories resonating with the audience and will oversee the development of Stan Lee's never-before-seen properties. The company acquired the Stan Lee rights to over 100 IPs under the Stan Lee Universal banner.

Recently the company launched its first iOS Kartoon Channel! App. The company's CEO and Chairman Andy Heyward said they were pleased with how fast Kartoon Channe! had been discovered. Following the launch, the number of parents that had downloaded the app for their kids skyrocketed leading to the app climbing the top ten lists for kids.

AIM ImmunoTech Enters Agreement For Its Phase 1/2a COVID-19 Vaccine Studies

https://themarketsignal.com/Free-Report/AIM

(Click the link above or copy, paste and hit enter in your browser for your report)

AIM ImmunoTech (NASDAQ:AIM) has also surged this year and the stock is up 449.63%% year to date. The company indicated that it had signed a clinical trial deal with Roswell Park Comprehensive Cancer Centre for its Phase 1/2a study of Ampligen in combo with interferon alfa-2b for treatment of COVID-19 cancer patients. TAIM ImmunoTech CEO Tom Equels indicated that the company had also signed an agreement with the National Institute of Infectious Diseases of Japan and pharmaceutical firm Shionogi & Co Ltd for testing on its Ampligen drug as a COVID-19 vaccine enhancer.

Alpha Pro Tech Posts 123.4% Increase In Net Sales In Q2 2020

https://themarketsignal.com/Free-Report/APT

(Click the link above or copy, paste and hit enter in your browser for your report)

Another stock that has surged year to date is Alpha Pro Tech (NYSE:APT) which is up 431.78%. The company has announced its Q2 2020 financial results in which it reported a 123.4% YoY increase in net sales to $25.5 million compared to Q2 2019 when it recorded $11.4 million. Net income in the quarter was around $6.2 million or 46 cents per share relative to 8 cents per share reported last year which represents YoY growth of 475%.

The CEO of the company Lloyd Hoffman said that they had an exceptional quarter with gross margin increasing 50% which was due to the change of the products to focus on PPEs and strong cash flow. Hoffman stated that there is a backlog of orders for N-95 masks and other PPEs and they have commitments for up to Q2 2021.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market, and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

comtex tracking

COMTEX_369169947/2700/2020-08-10T10:06:58

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.